#oncology #Mitazalimab #survivalrates #phase2study #survivalbenefit #AlligatorBioscience #phase2clincialtrial #OPTIMIZE1study #combinationtherapy #mFOLFIRINOX #metastaticpancreaticcancer #pancreaticcancer #pancreaticcancerpatients #clinicaltrials #drugdevelopment
pharmatimes.com/news/mitazal...
pharmatimes.com/news/mitazal...
Mitazalimab shows promising survival rates in cancer study - PharmaTimes
Updated data from phase 2 study reveals survival benefit
pharmatimes.com
February 28, 2025 at 9:48 AM
#immunotherapy #AlligatorBioscience #mitazalimab #mFOLFIRINOX #pancreaticcancer #metastaticpancreaticadenocarcinomacancer #mPDAC #mPDACpatients #OPTIMIZE1trial #metastaticpancreaticcancertreatment #healthoutcomesresearch #ASCOGastrointestinalCancersSymposium
pharmatimes.com/news/alligat...
pharmatimes.com/news/alligat...
Alligator Bioscience reports survival benefit of mitazalimab with mFOLFIRINOX - PharmaTimes
Comparison shows improved survival rates for pancreatic cancer treatment
pharmatimes.com
January 31, 2025 at 11:34 AM